Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Cannabis Bioscience International Holdings (CBIH) Research & Development (2022 - 2026)

Cannabis Bioscience International Holdings filings provide 5 years of Research & Development readings, the most recent being $983.0 for Q1 2026.

  • On a quarterly basis, Research & Development rose 357.21% to $983.0 in Q1 2026 year-over-year; TTM through Feb 2026 was $1321.0, a 106.41% increase, with the full-year FY2025 number at $517.0, down 74.96% from a year prior.
  • Research & Development reached $983.0 in Q1 2026 per CBIH's latest filing, up from $62.0 in the prior quarter.
  • The five-year high for Research & Development was $1772.0 in Q1 2023, with the low at $62.0 in Q4 2025.
  • A 5-year average of $661.64 and a median of $214.0 in 2025 define the central range for Research & Development.
  • Year-over-year, Research & Development crashed 91.65% in 2024 and then skyrocketed 357.21% in 2026.
  • Year by year, Research & Development stood at $1548.0 in 2022, then crashed by 87.27% to $197.0 in 2023, then tumbled by 50.76% to $97.0 in 2024, then tumbled by 36.08% to $62.0 in 2025, then soared by 1485.48% to $983.0 in 2026.
  • Per Business Quant, the three most recent readings for CBIH's Research & Development are $983.0 (Q1 2026), $62.0 (Q4 2025), and $213.0 (Q3 2025).